ArticleFrontiers in cardiovascular medicine2026
Lactate dehydrogenase-to-albumin ratio and adverse outcomes in patients with HFrEF and HFmrEF.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study investigated the association between lactate dehydrogenase-to-albumin ratio (LAR) and adverse outcomes in patients with heart failure with reduced ejection fraction (HFrEF) and heart failure with mildly reduced ejection fraction (HFmrEF). Methods: This retrospective cohort study included 1,084 hospitalised patients with HFrEF or HFmrEF. It was approved by the Ethics Committee. Associations between LAR and endpoint events(HF-related readmissions, all-cause deaths, composite endpoints) were assessed using Cox regression, Kaplan-Meier curves, and restricted cubic spline analysis. The Fine-Grey model was applied for HF-related readmission to account for competing mortality. Subgroup and sensitivity analyses were performed to evaluate the robustness of the findings. Incremental predictive value of LAR was assessed using C-index, NRI, and IDI. Results: During a mean follow-up of 29.3 months, higher LAR was independently associated with increased risks of HF-related readmissions(HR:1.602, 95% CI:1.088-2.359), all-cause mortality (HR:2.008, 95% CI:1.155-3.492), and the composite endpoint (HR:1.648, 95% CI:1.184-2.295) (all Conclusion: Baseline LAR level is an independent predictor of HF readmission, all-cause mortality, and the combined endpoint in both HFrEF and HFmrEF patients, demonstrating clinical value for risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.